Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Prophylactic and Therapeutic Anticoagulation in Hospitalized COVID-19 Patients: A Randomized Clinical Trial

  • By

  • Mahir Karakas

  • Shiva Sophia Nicolay

  • Dominic Wichmann

  • Stefan Schmiedel

  • Marylyn M. Addo

  • Anna Nosko

  • Natalie Lund

  • Apurva Shrivastava

  • Isabell Pink

  • Daniel Duerschmied

  • Nadine Gauchel

  • Elisabeth Schnoy

  • Ulrich-Frank Pape

  • Berthold Bein

  • Philipp Brasch

  • Dirk Arnold

  • Katrin Maevers

  • Sebastian Rasch

  • Johanna Erber

  • Tobias Lahmer

  • Tanja Zeller

  • Florian Langer

  • Ann-Kathrin Ozga

  • Anna Suling

  • Antonia Zapf

  • Dominik Jarczak

  • Stefan Kluge

  • September 23, 2026

Share

  • 1

    Coagulopathy in COVID-19 patients increases the risk of deep vein thromboses and pulmonary embolisms, leading to higher morbidity and mortality.

  • 2

    The HERO-19 trial compared therapeutic-dose anticoagulation with prophylactic dosing in hospitalized COVID-19 patients to assess clinical outcomes.

  • 3

    Therapeutic-dose anticoagulation involved full-dose low-molecular-weight heparin or fondaparinux during hospitalization, followed by edoxaban.

  • 4

    The trial was a multicenter, assessor-blinded, randomized clinical trial conducted across 10 German university hospitals.

  • 5

    A total of 140 patients were randomized, with 139 available for analysis after excluding one due to preexisting atrial fibrillation.

Original Source(s)

Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical

  • by Mahir Karakas, Shiva Sophia Nicolay, Dominic Wichmann, Stefan Schmiedel, Marylyn M. Addo, Anna Nosko, Natalie Lund, Apurva Shrivastava, Isabell Pink, Daniel Duerschmied, Nadine Gauchel, Elisabeth Schnoy, Ulrich-Frank Pape, Berthold Bein, Philipp Brasch, Dirk Arnold, Katrin Maevers, Sebastian Rasch, Johanna Erber, Tobias Lahmer, Tanja Zeller, Florian Langer, Ann-Kathrin Ozga, Anna Suling, Antonia Zapf, Dominik Jarczak, Stefan Kluge

  • September 23, 2026

Related Content

44,000 Protein Forms Mapped in Plasma

DIA mass spectrometry maps extensive proteoform diversity in human plasma

  • October 19, 2026

  • 3 min
Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

Response to Zhou and Shan: Interpreting long-term response to rituximab in immune thrombocytopenia